Evidence map›Paper›PMID 30896999›Full record

ArticleAmerican journal of public health2019

US Emergency Department Visits for Acute Harms From Prescription Opioid Use, 2016-2017.

Maribeth C Lovegrove, Deborah Dowell, Andrew I Geller, Sandra K Goring, Kathleen O Rose, Nina J Weidle, Daniel S Budnitz

Open access · greenAbstract read
In one paragraph

Article in American journal of public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Medications at the Emergency Department After Recent Rape.Journal of interpersonal violence · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Maribeth C LovegroveMaribeth C. Lovegrove, Andrew I. Geller, and Daniel S. Budnitz are with the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Deborah Dowell is with the National Center for Injury Prevention and Control, CDC. Sandra K. Goring and Kathleen O. Rose are with Northrup Grumman Corporation, Atlanta. Nina J. Weidle is with Eagle Medical Services LLC, Atlanta.
Deborah DowellMaribeth C. Lovegrove, Andrew I. Geller, and Daniel S. Budnitz are with the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Deborah Dowell is with the National Center for Injury Prevention and Control, CDC. Sandra K. Goring and Kathleen O. Rose are with Northrup Grumman Corporation, Atlanta. Nina J. Weidle is with Eagle Medical Services LLC, Atlanta.
Andrew I GellerMaribeth C. Lovegrove, Andrew I. Geller, and Daniel S. Budnitz are with the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Deborah Dowell is with the National Center for Injury Prevention and Control, CDC. Sandra K. Goring and Kathleen O. Rose are with Northrup Grumman Corporation, Atlanta. Nina J. Weidle is with Eagle Medical Services LLC, Atlanta.
Sandra K GoringMaribeth C. Lovegrove, Andrew I. Geller, and Daniel S. Budnitz are with the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Deborah Dowell is with the National Center for Injury Prevention and Control, CDC. Sandra K. Goring and Kathleen O. Rose are with Northrup Grumman Corporation, Atlanta. Nina J. Weidle is with Eagle Medical Services LLC, Atlanta.
Kathleen O RoseMaribeth C. Lovegrove, Andrew I. Geller, and Daniel S. Budnitz are with the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Deborah Dowell is with the National Center for Injury Prevention and Control, CDC. Sandra K. Goring and Kathleen O. Rose are with Northrup Grumman Corporation, Atlanta. Nina J. Weidle is with Eagle Medical Services LLC, Atlanta.
Nina J WeidleMaribeth C. Lovegrove, Andrew I. Geller, and Daniel S. Budnitz are with the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Deborah Dowell is with the National Center for Injury Prevention and Control, CDC. Sandra K. Goring and Kathleen O. Rose are with Northrup Grumman Corporation, Atlanta. Nina J. Weidle is with Eagle Medical Services LLC, Atlanta.
Daniel S BudnitzMaribeth C. Lovegrove, Andrew I. Geller, and Daniel S. Budnitz are with the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Deborah Dowell is with the National Center for Injury Prevention and Control, CDC. Sandra K. Goring and Kathleen O. Rose are with Northrup Grumman Corporation, Atlanta. Nina J. Weidle is with Eagle Medical Services LLC, Atlanta.
The Centers · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo estimate the number of US emergency department visits for prescription opioid harms by patient characteristics, intent, clinical manifestations, and active ingredient.

methodsWe used data from medical record-based surveillance from a nationally representative 60-hospital sample.

resultsBased on 7769 cases, there were 267 020 estimated emergency department visits annually (95% confidence interval [CI] = 209 833, 324 206) for prescription opioid harms from 2016 to 2017. Nearly half of visits (47.6%; 95% CI = 40.8%, 54.4%) were attributable to nonmedical opioid use, 38.9% (95% CI = 32.9%, 44.8%) to therapeutic use, and 13.5% (95% CI = 11.0%, 16.0%) to self-harm. Co-implication with other pharmaceuticals and concurrent illicit drug and alcohol use were common; prescription opioids alone were implicated in 31.5% (95% CI = 27.2%, 35.8%) of nonmedical use visits and 19.7% (95% CI = 15.7%, 23.7%) of self-harm visits. Unresponsiveness or cardiorespiratory failure (30.0%) and altered mental status (35.7%) were common in nonmedical use visits. Gastrointestinal effects (30.4%) were common in therapeutic use visits. Oxycodone was implicated in more than one third of visits across intents.

conclusionsMorbidity data can help target interventions, such as dispensing naloxone to family and friends of those with serious overdose, and screening and treatment of substance use disorder when opioids are prescribed long-term.

Indexed as

Emergency Service, HospitalDrug OverdoseFemaleHumansMaleOpioid-Related DisordersPain ManagementPrescription Drug OveruseUnited States

Identifiers

PMID30896999
PMCPMC6459659
OpenAlexW2923135510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.